Team 5: Atherothrombotic Disease in Heart and Brain

Group leader: Gabriel STEG

ClinicalresearchTeam 5 “Translational research on cardio- and cerebrovascular disease” started with an innovative collaboration of cardiologists and neurologists (formerly within the “clinical research on atherothrombosis” team) implemented by basic science researchers, coming from the former team on “Vascular Remodelling”. Our projects are focussed on 1/ international clinical trials assessing medical strategies and new therapies in coronary artery disease and cerebrovascular disease, particularly acute coronary syndromes and stroke, and 2/ on translational research aiming to uncover new biological markers of atherothrombosis in humans as a basis for new diagnostic/theranostic tools, but also for developing new therapeutic tools (in particular HDL-based therapies).

There is a dire need for therapies to help address the cardiovascular consequences of the diabetes and obesity epidemic. While important, this is not limited to the development of more potent and safer agents to prevent thrombosis, stabilize or prevent atherosclerosis, or treat hyperglycemia. The potential hazards (on cardiovascular mortality) of aggressive management of hyperglycemia have emphasized the need to fully assess the cardiovascular impact of antidiabetic drugs. Recent clinical trials also underlined the importance of rigorous evaluation of the clinical effectiveness of routine therapeutic strategies. Future treatments will need to demonstrate safety and cost-effectiveness in addition to efficacy. Our aim is to focus on new, effective, safe, affordable and easily implementable therapeutic strategies for atherothrombosis and diabetes.

Link to the Group on “Eicosanoids & Vascular Pharmacology”

Family name
First name
Position
Tel
Email
ABERGELHélèneIR01.57.27.53.57helene.abergel@aphp.fr
ABTANJérémieDoctorantVIDE
AMARENCOPierrePUPH101.40.25.87.25pierre.amarenco@aphp.fr
BADJIHichem AhmedDoctorant01.40.25.75.29hichem.badji@inserm.fr
BOUFFARDCatherineTCHcatherine.bouffard@aphp.fr
BOUHADOUNAmelDoctorant01.40.25.75.29amelbouhadoun@gmail.com
CIMADEVILLAClairePHclaire.cimadevilla@aphp.fr
DUCROCQGregoryPUPHgregory.ducrocq@aphp.fr
ELBEZYedidAutre_ECyedid.elbez@aphp.fr
FARNOUDRezaIR01.57.27.53.52reza.farnoud@bch.aphp.fr
FELDMANLaurentPUPH101.40.25.66.01laurent.feldman@aphp.fr
FUENTESAxelleContrat à durée déterminée (catégorie B)axelle.fuentes@gmail.com
JULIARDJean-MichelPH01.40.25.85.21jean-michel.juliard@aphp.fr
LAVALLEEPhilippaMCUPH01.40.25.70.33philippalavallee@yahoo.fr
LONGROISDanPUPH101.40.25.74.27dan.longrois@aphp.fr
MERHEBGaelleM2gaelle.merheb@etu.u-paris.fr
MESEGUER GANCEDOElenaPH01.40.25.74.90elena.meseguer@aphp.fr
NGUYENCarolineCCA01.40.25.83.53caroline.nguyen@aphp.fr
NORELXavierIR01.40.25.75.29xnorel@hotmail.com
RENSONLouisM2louis.renson@aphp.fr
SIMONTabassomePUPHtabassome.simon@sat.aphp.fr
SORBETSEmmanuelPHemmanuel.sorbets@aphp.fr
SPIELERJean-FrançoisMCF01.40.25.87.28jean-francois.spieler@aphp.fr
STEGPhilippe GabrielPUPH101.40.25.73.25gabriel.steg@aphp.fr
TOUBOULPierre-JeanPUPH01.40.25.87.25pjtw@noos.fr

Publications

1.
Roustit M, Demarcq O, Laporte S, Barthélémy P, Chassany O, Cucherat M, Demotes J, Diebolt V, Espérou H, Fouret C, Galaup A, Gambotti L, Gourio C, Guérin A, Labruyère C, Paoletti X, Porcher R, Simon T, Varoqueaux N. 2022. Platform trials. Therapie https://doi.org/10.1016/j.therap.2022.12.003.
1.
Pico F, Labreuche J, Amarenco P. 2022. Remote Ischemic Conditioning vs Usual Care and Neurologic Function in Acute Moderate Ischemic Stroke. Jama 328:2362–2363.
1.
Hascoët S, Smolka G, Kilic T, Ibrahim R, Onorato EM, Calvert PA, Champagnac D, Freixa-Rofastes X, Zorinas A, Sandoval JP, Ducrocq G, Bouisset F, Fraisse A, Gerardin B. 2022. Procedural Tools and Technics for Transcatheter Paravalvular Leak Closure: Lessons from a Decade of Experience. J Clin Med 12.
1.
Bouhadoun A, Manikpurage HD, Deschildre C, Zalghout S, Dubourdeau M, Urbach V, Ho-Tin-Noe B, Deschamps L, Michel JB, Longrois D, Norel X. 2022. DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE(2). Prostaglandins Other Lipid Mediat 165:106700.
1.
White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristić AD, Zeiher AM, Wojdyla DM, Steg PG. 2022. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 43:1554–1565.
1.
Weizman O, Marijon E, Narayanan K, Boveda S, Defaye P, Martins R, Deharo JC, Laurent G, Klug D, Sadoul N, Hocini M, Mansencal N, Anselme F, Da Costa A, Maury P, Ferrières J, Schiele F, Simon T, Danchin N. 2022. Incidence, Characteristics, and Outcomes of Ventricular Fibrillation Complicating Acute Myocardial Infarction in Women Admitted Alive in the Hospital. J Am Heart Assoc 11:e025959.
1.
Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Johnston SC. 2022. Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology 99:e46–e54.
1.
Vergès B, Aboyans V, Angoulvant D, Boutouyrie P, Cariou B, Hyafil F, Mohammedi K, Amarenco P. 2022. Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. Cardiovasc Diabetol 21:242.
1.
Tea V, Morelle JF, Gallet R, Cayla G, Lemesle G, Lhermusier T, Dillinger JG, Ducrocq G, Angouvant D, Cottin Y, Chamandi C, le Bras A, Steg PG, Montalescot G, Nelson AC, Simon T, Chatellier G, Danchin N, Puymirat E. 2022. Immediate versus staged complete myocardial revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A post hoc analysis of the randomized FLOWER-MI trial. Arch Cardiovasc Dis 115:496–504.
1.
Steg PG, Kikoïne J. 2022. Do We Need Ischemia Testing to Monitor Asymptomatic Patients With Chronic Coronary Syndromes? Circulation https://doi.org/10.1161/circulationaha.122.053565.
1.
Steg PG, Bhatt DL, James SK, Darlington O, Hoskin L, Simon T, Fox KM, Leiter LA, Mehta SR, Harrington RA, Himmelmann A, Ridderstråle W, Andersson M, Bueno H, De Luca L, Tank A, Mellström C, McEwan P. 2022. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother 8:777–785.
1.
Sidhu MS, Alexander KP, Huang Z, O’Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, Maron DJ. 2022. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. Am Heart J 248:72–83.
1.
Scotti A, Coisne A, Taramasso M, Granada JF, Ludwig S, Rodés-Cabau J, Lurz P, Hausleiter J, Fam N, Kodali SK, Rosiene J, Feinberg A, Pozzoli A, Alessandrini H, Biasco L, Brochet E, Denti P, Estevez-Loureiro R, Frerker C, Ho EC, Monivas V, Nickenig G, Praz F, Puri R, Sievert H, Tang GHL, Andreas M, Von Bardeleben RS, Rommel KP, Muntané-Carol G, Gavazzoni M, Braun D, Koell B, Kalbacher D, Connelly KA, Juliard JM, Harr C, Pedrazzini G, Russo G, Philippon F, Schofer J, Thiele H, Unterhuber M, Himbert D, Alcázar MU, Wild MG, Windecker S, Jorde U, Maisano F, Leon MB, Hahn RT, Latib A. 2022. Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation. Eur Heart J https://doi.org/10.1093/eurheartj/ehac735.
1.
Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Diener HC, Gailani D, Kahl A, Donovan M, Perera V, Li D, Hankey GJ. 2022. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. J Stroke Cerebrovasc Dis 31:106742.
1.
Sebag FA, Garot P, Galea R, De Backer O, Lepillier A, De Meesteer A, Hildick-Smith D, Armero S, Moubarak G, Ducrocq G, Eschalier R, Aminian A, Sauguet A, Lellouche N, Mahmoudi K, Räber L, Amabile N. 2022. Left atrial appendage closure for thrombus trapping: the international, multicentre TRAPEUR registry. EuroIntervention 18:50–57.
1.
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, Bagai A, Granger CB, Cohen MG, Yasuda S, Nicolau JC, Brandrup-Wognsen G, Westermann D, Simon T, Goodman SG. 2022. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J Cardiol 79:522–529.
1.
Rouen A, Rogers E, Kerlan V, Delemer B, Catteau-Jonard S, Reznik Y, Gompel A, Cedrin I, Guedj AM, Grouthier V, Brue T, Pienkowski C, Bachelot A, Chantot-Bastaraud S, Rousseau A, Simon T, Kott E, Siffroi JP, Touraine P, Christin-Maitre S. 2022. Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families. Fertil Steril 117:843–853.
1.
Robert R, Cottin Y, Potard V, Mary-Krause M, Lang S, Teiger E, Collet JP, Chauvet-Droit M, Ederhy S, Soulat-Dufour L, Ancedy Y, Adavane-Scheuble S, Nhan P, Steg PG, Funck-Brentano C, Costagliola D, Cohen A, Boccara F. 2022. Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. Circ Cardiovasc Interv 15:e011945.
1.
Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. 2022. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc 11:e026229.
1.
Pham V, Bonnet M, Varenne O, Lafont A, Darmon A, Feldman L, Rioufol G, Derimay F, Harbaoui B, Picard F. 2022. In-Stent Use of Intravascular Coronary Lithotripsy for Restenosis and Stent Underexpansion: A Multicentre Experience. Can J Cardiol 38:1474–1475.
1.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, Fernandez A, Filippatos G, Jering K, Landmesser U, Menon V, Merkely B, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Wang Y, Braunwald E. 2022. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation 145:87–89.
1.
Ozen G, Aljesri K, Turkyilmaz G, Turkyilmaz S, Kavala AA, Topal G, Norel X. 2022. Comparative study of coronary artery bypass graft materials: reduced contraction and ADMA levels in internal mammary artery versus saphenous vein. J Cardiovasc Surg (Torino) 63:69–77.
1.
Ono M, Tomaniak M, Koenig W, Khamis R, de Silva R, Chichareon P, Kawashima H, Hara H, Gao C, Wang R, Huber K, Vrolix M, Jasionowicz P, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Windecker S, Onuma Y, Storey RF, Serruys PW. 2022. Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. Eur Heart J Cardiovasc Pharmacother 8:39–47.
1.
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG. 2022. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 10:330–340.
1.
Ono M, Hara H, Kawashima H, Gao C, Wang R, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, Valgimigli M, Windecker S, Vranckx P, Onuma Y, Serruys PW. 2022. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention 18:e377–e388.
1.
Nguyen C, Celestin E, Chambolle D, Linglart A, Biosse Duplan M, Chaussain C, Friedlander L. 2022. Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. Endocr Connect 11.
1.
Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H. 2022. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 10:26–34.
1.
Moriarty PM, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, Pordy R, Loy M, Jukema JW, Harrington RA, Gray JV, Gorby LK, Goodman SG, Diaz R, Bittner VA, Bhatt DL, Szarek M, Schwartz GG. 2022. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. J Clin Lipidol 16:747–756.
1.
Mikail N, Meseguer E, Lavallée P, Klein I, Hobeanu C, Guidoux C, Cabrejo L, Lesèche G, Amarenco P, Hyafil F. 2022. Evaluation of non-stenotic carotid atherosclerotic plaques with combined FDG-PET imaging and CT angiography in patients with ischemic stroke of unknown origin. J Nucl Cardiol 29:1329–1336.
1.
Mehta SR, Wang J, Wood DA, Spertus JA, Cohen DJ, Mehran R, Storey RF, Steg PG, Pinilla-Echeverri N, Sheth T, Bainey KR, Bangalore S, Cantor WJ, Faxon DP, Feldman LJ, Jolly SS, Kunadian V, Lavi S, Lopez-Sendon J, Madan M, Moreno R, Rao SV, Rodés-Cabau J, Stankovic G, Bangdiwala SI, Cairns JA. 2022. Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial. JAMA Cardiol 7:1091–1099.
1.
Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, Granger C, Køber L, Maggioni A, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Ducrocq G, Berwanger O, De Pasquale CG, Landmesser U, Petrie M, Leng DSK, van der Meer P, Lefkowitz M, Zhou Y, Braunwald E. 2022. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation 146:1749–1757.
1.
Luong Nguyen LB, Ghosn J, Durier C, Tachot C, Tartour E, Touati A, Simon T, Autran B, Ortega Perez I, Telford E, Ward JK, Michels D, Meyer L, Rousseau A, Berard L, de Lamballerie X, Launay O. 2022. A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox. Nat Med 28:1983–1984.
1.
Mak KH, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I, Tendera M, Ferrari R, Tardif JC, Udell JA, Escobedo J, Fox KM, Steg PG. 2022. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. Eur J Prev Cardiol 28:1795–1806.
1.
Lopes RD, Guimarães PO, Schwartz GG, Bhatt DL, Bittner VA, Budaj A, Dalby AJ, Diaz R, Goodman SG, Harrington RA, Jukema JW, Kiss RG, Loy M, Pordy R, Poulouin Y, Szarek M, White HD, Steg PG. 2022. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. Am J Med 135:915–918.
1.
Lim P, Delmas C, Sanchez O, Meneveau N, Rosario R, Bouvaist H, Bernard A, Mansourati J, Couturaud F, Sebbane M, Coste P, Rohel G, Tardy B, Biendel C, Lairez O, Ivanes F, Gallet R, Dubois-Rande JL, Fard D, Chatelier G, Simon T, Paul M, Natella PA, Layese R, Bastuji-Garin S. 2022. Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial. Eur Heart J Acute Cardiovasc Care 11:2–9.
1.
Lemesle G, Puymirat E, Bonello L, Simon T, Steg PG, Ferrières J, Schiele F, Fauchier L, Henry P, Schurtz G, Ninni S, Lamblin N, Bauters C, Danchin N. 2022. Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease. Diabetes Metab 48:101265.
1.
Le Bras A, Puymirat E, Rabetrano H, Cayla G, Simon T, Steg G, Montalescot G, Varenne O, Bonello L, Coste P, Delarche N, Georges JL, Chassaing S, Letocart V, Chatellier G, Danchin N, Durand-Zaleski I. 2022. Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trial. EuroIntervention 18:235–241.
1.
Laviolle B, Diebolt V, Duchossoy L, Anglaret X, Béhier JM, Bertoye PH, Chapron A, Comet D, Cornu C, Fouret C, Galaup A, Guérin A, Hoen B, Imbert P, Lang M, Le Louarn A, Mezerette B, Sénéchal S, Simon T, Traineau P. 2022. Outpatient healthcare and clinical trials in the care pathway: Organisational and regulatory aspects and tools. Therapie 77:37–48.
1.
Laviolle B, Diebolt V, Duchossoy L, Anglaret X, Béhier JM, Bertoye PH, Chapron A, Comet D, Cornu C, Fouret C, Galaup A, Guérin A, Hoen B, Imbert P, Lang M, Le Louarn A, Mezerette B, Sénéchal S, Simon T, Traineau P. 2022. [Not Available]. Therapie 77:25–36.
1.
Launay O, Cachanado M, Luong Nguyen LB, Ninove L, Lachâtre M, Ben Ghezala I, Bardou M, Schmidt-Mutter C, Lacombe K, Laine F, Allain JS, Botelho-Nevers E, Tavolacci MP, Chidiac C, Pavese P, Dussol B, Priet S, Deplanque D, Touati A, Curci L, Konate E, Ben Hamouda N, Besbes A, Nubret E, Capelle F, Berard L, Rousseau A, Tartour E, Simon T, de Lamballerie X. 2022. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. N Engl J Med 387:374–376.
1.
Kooshki N, Grambow-Velilla J, Mahida B, Benali K, Nguyen C, Cimadevilla C, Braham W, Pisani A, Iung B, Raffoul R, Rouzet F, Hyafil F. 2022. Diagnostic performance of White Blood Cell SPECT imaging against intra-operative findings in patients with a suspicion of prosthetic valve endocarditis. J Nucl Cardiol 29:528–534.
1.
Khoury R, Dupin C, Nguyen C, Halut M, Mordant P, Khalil A. 2022. Unusual Case of High-Flow Left Heart Failure: Physiopathology, Multimodality Imaging, and Endovascular Management. Circ Cardiovasc Imaging 101161circimaging122014219.
1.
Kalfon P, Payen JF, Rousseau A, Chousterman B, Cachanado M, Tibi A, Audibert J, Depret F, Constantin JM, Weiss E, Remerand F, Freund Y, Simon T, Riou B. 2022. Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine 52:101663.
1.
Kerneis M, Cosentino F, Ferrari R, Georges JL, Kosmachova E, Laroche C, Maggioni AP, Rittger H, Steg PG, Maczynska J, Tavazzi L, Valgimigli M, Gale CP, Komajda M. 2022. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry. Eur J Prev Cardiol 29:1945–1954.
1.
Johnson PI, Favela K, Jarin J, Le AM, Clark PY, Fu L, Gillis AD, Morga N, Nguyen C, Harley KG. 2022. Chemicals of concern in personal care products used by women of color in three communities of California. J Expo Sci Environ Epidemiol 1–13.
1.
Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, Mahaffey KW, Gibson CM, Steg PG, Stone GW, Bhatt DL. 2022. Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. Am J Cardiovasc Drugs 22:93–104.
1.
Janssen C, Cachanado M, Ninove L, Lachatre M, Michon J, Epaulard O, Maakaroun-Vermesse Z, Chidiac C, Laviolle B, Aumaitre H, Assaf A, Lacombe K, Schmidt-Mutter C, Botelho-Nevers E, Briere M, Boisson T, Loubet P, Bienvenu B, Bouchaud O, Touati A, Pereira C, Rousseau A, Berard L, Montil M, de Lamballerie X, Simon T, Launay O. 2022. Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial. EClinicalMedicine 48:101444.
1.
Hobeanu C, Lavallée PC, Charles H, Labreuche J, Albers GW, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina CA, Rothwell PM, Steg PG, Touboul PJ, Uchiyama S, Vicaut E, Wong KSL, Amarenco P. 2022. Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study. Lancet Neurol 21:889–898.
1.
Hermine O, Mariette X, Porcher R, Djossou F, Nguyen Y, Arlet JB, Savale L, Diehl JL, Georgin-Lavialle S, Cadranel J, Pialoux G, Lacombe K, Mekinian A, Gros H, Lescure X, Ghosn J, Coupez E, Grapin K, Rapp C, Michel M, Lecapitaine AL, Michot JM, Costedoat-Chalumeau N, Nguyen LBL, Semerano L, Raffi F, Aguillar C, Rouzaud C, Gottenberg JE, Hansmann Y, Bienvenu B, London J, Fantchou FS, Ackermann F, Gros A, Morel A, Gambier N, Sène D, Mégarbane B, Azoulay E, Bureau S, Dougados M, Emmerich J, Fartoukh M, Guidet B, Humbert M, Mahevas M, Pène F, Schlemmer F, Pourcher-Martinez V, Tibi A, Baron G, Perrodeau E, Baron S, Steg G, Yazdapanah Y, Simon T, Resche-Rigon M, Tharaux PL, Ravaud P. 2022. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group. EClinicalMedicine 46:101362.
1.
Henriksen BT, Krogseth M, Nguyen CT, Mathiesen L, Davies MN, Andersen RD, Andersson Y. 2022. Medication management for patients with hip fracture at a regional hospital and associated primary care units in Norway: a descriptive study based on a survey of clinicians’ experience and a review of patient records. BMJ Open 12:e064868.
1.
Zeymer U, Leiva O, Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Gabor Kiss R, Ongen Z, Navarro Estrada J, Oude Ophuis T, Lip GYH, Nordaby M, Miede C, Ten Berg JM, Bhatt DL, Cannon CP. 2021. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention 17:474–480.
1.
White HD, Steg PG, Schwartz GG. 2021. Myocardial Infarction and Evolocumab. JAMA Cardiol 6:1220–1221.
1.
Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Birve F, Ladenvall P, Molina CA, Johnston SC. 2021. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. JAMA Neurol 78:1091–1098.
1.
Vranckx P, Valgimigli M, Odutayo A, Serruys PW, Hamm C, Steg PG, Heg D, Mc Fadden EP, Onuma Y, Benit E, Janssens L, Diletti R, Ferrario M, Huber K, Räber L, Windecker S, Jüni P. 2021. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial. J Am Heart Assoc 10:e015560.
1.
Voiriot G, Fartoukh M, Durand-Zaleski I, Berard L, Rousseau A, Armand-Lefevre L, Verdet C, Argaud L, Klouche K, Megarbane B, Patrier J, Richard JC, Reignier J, Schwebel C, Souweine B, Tandjaoui-Lambiotte Y, Simon T, Timsit JF. 2021. Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units. BMJ Open 11:e048187.
1.
Van Spall HGC, Lala A, Deering TF, Casadei B, Zannad F, Kaul P, Mehran R, Pearson GD, Shah MR, Gulati M, Grines C, Volgman AS, Revkin JH, Piña I, Lam CSP, Hochman JS, Simon T, Walsh MN, Bozkurt B. 2021. Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week. J Am Coll Cardiol 77:2960–2972.
1.
Vallée A, Sorbets E, Lelong H, Langrand J, Blacher J. 2021. The lead story of the fire at the Notre-Dame cathedral of Paris. Environ Pollut 269:116140.
1.
Urena M, Vahanian A, Brochet E, Ducrocq G, Iung B, Himbert D. 2021. Current Indications for Transcatheter Mitral Valve Replacement Using Transcatheter Aortic Valves: Valve-in-Valve, Valve-in-Ring, and Valve-in-Mitral Annulus Calcification. Circulation 143:178–196.
1.
Urena M, Lemann T, Chong-Nguyen C, Brochet E, Ducrocq G, Carrasco JL, Iung B, Vahanian A, Himbert D. 2021. Causes and predictors of mortality after transcatheter mitral valve implantation in patients with severe mitral annulus calcification. Catheter Cardiovasc Interv 98:981–989.
1.
Uchiyama S, Hoshino T, Charles H, Kamiyama K, Nakase T, Kitagawa K, Minematsu K, Todo K, Okada Y, Nakagawara J, Nagata K, Yamagami H, Yamaguchi T, Amarenco P. 2021. Japanese and Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke: A Five-Year Risk Analysis of Stroke and Vascular Events. J Atheroscler Thromb 28:656–664.
1.
Tsiantoulas D, Eslami M, Obermayer G, Clement M, Smeets D, Mayer FJ, Kiss MG, Enders L, Weißer J, Göderle L, Lambert J, Frommlet F, Mueller A, Hendrikx T, Ozsvar-Kozma M, Porsch F, Willen L, Afonyushkin T, Murphy JE, Fogelstrand P, Donzé O, Pasterkamp G, Hoke M, Kubicek S, Jørgensen HF, Danchin N, Simon T, Scharnagl H, März W, Borén J, Hess H, Mallat Z, Schneider P, Binder CJ. 2021. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. Nature 597:92–96.
1.
Trujillo-Estrada L, Vanderklish PW, Nguyen MMT, Kuang RR, Nguyen C, Huynh E, da Cunha C, Javonillo DI, Forner S, Martini AC, Sarraf ST, Simmon VF, Baglietto-Vargas D, LaFerla FM. 2021. SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease. Neurotherapeutics 18:2468–2483.
1.
Touir A, Boumiza S, Nasr HB, Bchir S, Tabka Z, Norel X, Chahed K. 2021. Prostaglandin Endoperoxide H Synthase-2 (PGHS-2) Variants and Risk of Obesity and Microvascular Dysfunction Among Tunisians: Relevance of rs5277 (306G/C) and rs5275 (8473T/C) Genetic Markers. Biochem Genet 59:1457–1486.
1.
Teiger E, Thambo JB, Defaye P, Hermida JS, Abbey S, Klug D, Juliard JM, Spaulding C, Armero S, Champagnac D, Bhugaloo H, Ternacle J, Lellouche N, Audureau E, Le Corvoisier P. 2021. Left atrial appendage closure for stroke prevention in atrial fibrillation: Final report from the French left atrial appendage closure registry. Catheter Cardiovasc Interv 98:788–799.
1.
Sulman D, Darmon A, Ducrocq G. 2021. A giant left ventricular calcified pseudoaneurysm 24 years following acute myocardial infarction: a case report. Eur Heart J Case Rep 5:ytab329.
1.
Simon T, Danchin N. 2021. Beware of simple explanations. Heart 107:348–349.
1.
Shim J, On YK, Kwon SU, Nam GB, Lee MH, Park HW, Hong KS, Kim NH, Amarenco P, Rha SW, Shin DG, Rha JH, Kim YH. 2021. A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea. Korean J Intern Med 36:906–913.
1.
Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG. 2021. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care 44:1219–1227.
1.
Sellam J, Maheu E, Crema MD, Touati A, Courties A, Tuffet S, Rousseau A, Chevalier X, Combe B, Dougados M, Fautrel B, Kloppenburg M, Laredo JD, Loeuille D, Miquel A, Rannou F, Richette P, Simon T, Berenbaum F. 2021. The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis - methodology and baseline characteristics of the population. Joint Bone Spine 88:105171.
1.
Schiele F, Gale CP, Simon T, Fox KAA, Bueno H, Lettino M, Tubaro M, Puymirat E, Ferrières J, Ecarnot F, Danchin N, Meneveau N. 2021. The 2020 ESC-ACVC quality indicators for the management of acute myocardial infarction applied to the FAST-MI registries. Eur Heart J Acute Cardiovasc Care 10:207–215.
1.
Santos-Zas I, Lemarié J, Zlatanova I, Cachanado M, Seghezzi JC, Benamer H, Goube P, Vandestienne M, Cohen R, Ezzo M, Duval V, Zhang Y, Su JB, Bizé A, Sambin L, Bonnin P, Branchereau M, Heymes C, Tanchot C, Vilar J, Delacroix C, Hulot JS, Cochain C, Bruneval P, Danchin N, Tedgui A, Mallat Z, Simon T, Ghaleh B, Silvestre JS, Ait-Oufella H. 2021. Cytotoxic CD8(+) T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun 12:1483.
1.
Schlotter F, Miura M, Kresoja KP, Alushi B, Alessandrini H, Attinger-Toller A, Besler C, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Estevez-Loureiro R, Fam N, Gavazzoni M, Himbert D, Ho EC, Juliard JM, Kalbacher D, Kaple R, Kreidel F, Latib A, Lubos E, Ludwig S, Mehr M, Monivas V, Nazif TM, Nickenig G, Pedrazzini G, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Rommel KP, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Unterhuber M, Vahanian A, von Bardeleben RS, von Roeder M, Webb JG, Weber M, Wild MG, Windecker S, Zuber M, Hausleiter J, Maisano F, Leon MB, Hahn RT, Lauten A, Taramasso M, Lurz P. 2021. Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention 17:e343–e352.
1.
Salmon-Ceron D, Slama D, De Broucker T, Karmochkine M, Pavie J, Sorbets E, Etienne N, Batisse D, Spiridon G, Baut VL, Meritet JF, Pichard E, Canouï-Poitrine F. 2021. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study. J Infect 82:e1–e4.
1.
Sacre K, Delaval L, Dossier A, Alexandra JF, Berleur M, Chauveheid MP, Ducrocq G, Goulenok T, van Gysel D, Rouzaud D, Papo T. 2021. New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion. Ann Rheum Dis 80:e190.
1.
Radiom M, Hénault R, Mani S, Iankovski AG, Norel X, Berret JF. 2021. Magnetic wire active microrheology of human respiratory mucus. Soft Matter 17:7585–7595.
1.
Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, le Bras A, Gallet R, Khalife K, Morelle JF, Motreff P, Lemesle G, Dillinger JG, Lhermusier T, Silvain J, Roule V, Labèque JN, Rangé G, Ducrocq G, Cottin Y, Blanchard D, Charles Nelson A, De Bruyne B, Chatellier G, Danchin N. 2021. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. N Engl J Med 385:297–308.
1.
Pocock S, Brieger DB, Owen R, Chen J, Cohen MG, Goodman S, Granger CB, Nicolau JC, Simon T, Westermann D, Yasuda S, Hedman K, Mellström C, Andersson Sundell K, Grieve R. 2021. Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. Open Heart 8.
1.
Picard F, Steg PG. 2021. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Curr Atheroscler Rep 23:27.
1.
Picard F, Bhatt DL, Ducrocq G, Ohman EM, Goto S, Eagle KA, Wilson PWF, Smith Jr SC, Elbez Y, Steg PG. 2021. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol 340:96–104.
1.
Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B. 2021. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses 13.
1.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E. 2021. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med 385:1845–1855.
1.
Pan Y, Wangqin R, Li H, Wang Y, Meng X, Johnston SC, Simon T, Lin J, Zhao X, Liu L, Wang D, Wang Y. 2021. F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. Neurology 96:e1–e9.
1.
Ozen G, Aljesri K, Abdelazeem H, Norel X, Turkyılmaz G, Turkyılmaz S, Topal G. 2021. Comparative study on the effect of aspirin, TP receptor antagonist and TxA(2) synthase inhibitor on the vascular tone of human saphenous vein and internal mammary artery. Life Sci 286:120073.
1.
Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan AW. 2021. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. Jama 326:257–265.
1.
Ono M, Kawashima H, Hara H, Gamal A, Wang R, Gao C, O’Leary N, Soliman O, Piek JJ, van Geuns RJ, Jüni P, Hamm CW, Valgimigli M, Vranckx P, Windecker S, Steg PG, Fox KA, Onuma Y, Serruys PW. 2021. External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. Catheter Cardiovasc Interv 98:E513-e522.
1.
Obadia M, Lamirel C, Meseguer E, Seners P, Zuber K, Rosenheim M, Yavchitz A, Bidot S, Hage R, Sabben C, Savatovsky J, Lavallée PC, Gout O, Vignal C, Amarenco P. 2021. Vascular origin in acute transient visual disturbance: A prospective study. Eur J Neurol 28:4098–4108.
1.
Nickenig G, Weber M, Schüler R, Hausleiter J, Nabauer M, von Bardeleben RS, Sotiriou E, Schäfer U, Deuschl F, Alessandrini H, Kreidel F, Juliard JM, Brochet E, Latib A, Montorfano M, Agricola E, Baldus S, Friedrichs KP, Deo SH, Gilmore SY, Feldman T, Hahn RT, Maisano F. 2021. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention 16:e1264–e1271.
1.
Muntané-Carol G, Taramasso M, Miura M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Lubos E, Ludwig S, Kalbacher D, Estevez-Loureiro R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Harr C, Lauten A, Lurz J, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Philippon F, Praz F, Puri R, Schäfer U, Schofer J, Sievert H, Tang GHL, Khattab AA, Andreas M, Russo M, Thiele H, Unterhuber M, Himbert D, Urena M, von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, Hahn RT, Rodés-Cabau J. 2021. Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. Circ Cardiovasc Interv 14:e009685.
1.
Muntané-Carol G, Taramasso M, Miura M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, Sievert H, Denti P, Lubos E, Ludwig S, Kalbacher D, Estevez-Loureiro R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Harr C, Lauten A, Lurz J, Kresoja KP, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Philippon F, Praz F, Puri R, Schäfer U, Schofer J, Tang GHL, Khattab AA, Andreas M, Russo M, Thiele H, Unterhuber M, Himbert D, Urena M, von Bardeleben RS, Webb JG, Weber M, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, Hahn RT, Rodés-Cabau J. 2021. Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Can J Cardiol 37:1094–1102.
1.
Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. 2021. International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Circulation 144:512–523.
1.
Mathieu d’Argent E, Ravel C, Rousseau A, Morcel K, Massin N, Sussfeld J, Simon T, Antoine JM, Mandelbaume J, Daraï E, Kolanska K. 2021. High-Dose Supplementation of Folic Acid in Infertile Men Improves IVF-ICSI Outcomes: A Randomized Controlled Trial (FOLFIV Trial). J Clin Med 10.
1.
Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. 2021. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med 14:e003006.
1.
Mariette X, Hermine O, Tharaux PL, Resche-Rigon M, Steg PG, Porcher R, Ravaud P. 2021. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Intern Med 181:1241–1243.
1.
Luo H, Zhang D, Taylor M, Nguyen C, Wang ZW. 2021. Aeration in sludge holding tanks as an economical means for biosolids odor control-A case study. Water Environ Res 93:1808–1818.
1.
Mani S, Norel X, Varret M, Bchir S, Ben Anes A, Garrouch A, Tabka Z, Longrois D, Chahed K. 2021. Polymorphisms rs2745557 in PTGS2 and rs2075797 in PTGER2 are associated with the risk of chronic obstructive pulmonary disease development in a Tunisian cohort. Prostaglandins Leukot Essent Fatty Acids 166:102252.
1.
Madhavan MV, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok NJ, Burton JR, Crowley A, Francese DP, Gupta A, C DERN, Chatterjee S, Palmerini T, Benedetto U, You SC, Ohman EM, Kastrati A, Steg PG, Gibson CM, Angiolillo DJ, Krumholz HM, Stone GW. 2021. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardiol Angiol 69:398–407.
1.
Luo H, Sun Y, Taylor M, Nguyen C, Strawn M, Broderick T, Wang ZW. 2021. Impacts of aluminum- and iron-based coagulants on municipal sludge anaerobic digestibility, dewaterability, and odor emission. Water Environ Res 94:e1684.
1.
Lellouche N, Arrouasse R, Ternacle J, Gallet R, Hermida JS, Hamon D, Juliard JM, Pasquie JL, Dhanjal T, Teiger E, Le Corvoisier P. 2021. Atrial fibrillation evolution and rhythm control strategy following left appendage closure: new insights from the prospective FLAAC registry. BMC Cardiovasc Disord 21:227.
1.
Leonardi S, Branca M, Franzone A, McFadden E, Piccolo R, Jüni P, Vranckx P, Steg PG, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Heg D, Windecker S, Valgimigli M. 2021. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. Circ Cardiovasc Qual Outcomes 14:e006581.
1.
Leiter LA, Bhatt DL, McGuire DK, Teoh H, Fox K, Simon T, Mehta SR, Lev EI, Kiss RG, Dalby AJ, Bueno H, Ridderstråle W, Himmelmann A, Prats J, Liu Y, Lee JJ, Amerena J, Kosiborod MN, Steg PG. 2021. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. J Am Coll Cardiol 77:2366–2377.
1.
Zijlstra LE, Schwartz GG, Steg PG, Jukema JW. 2020. Reply: Alirocumab in Polyvascular Atherosclerotic Disease. J Am Coll Cardiol 75:241.
1.
Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH. 2020. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol 75:1145–1155.
1.
Yang DH, Chubb DWR, Nguyen CT. 2020. Management of an Imminent Pathological Fracture of a Fibular Neomandible Via a Minimally Invasive Approach-A Case Report. J Prosthodont 29:746–750.
1.
Wise RA, Anderson JA, Amarenco P, Cowans NJ, Crim C, Denvir MA, Gomez CR, Jones MP, Morris A, Niewoehner D, Yates JC. 2020. Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. Clin Trials 17:430–436.
1.
White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L. 2020. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. Am Heart J 225:97–107.
1.
Weissberger GH, Goodman MC, Mosqueda L, Schoen J, Nguyen AL, Wilber KH, Gassoumis ZD, Nguyen CP, Han SD. 2020. Elder Abuse Characteristics Based on Calls to the National Center on Elder Abuse Resource Line. J Appl Gerontol 39:1078–1087.
1.
Weissberger G, Gibson K, Nguyen C, Han D. 2020. Neuropsychological case report of MCI reversion at one-year follow-up. Appl Neuropsychol Adult 27:284–293.
1.
Weissberger GH, Mosqueda L, Nguyen AL, Samek A, Boyle PA, Nguyen CP, Han SD. 2020. Physical and mental health correlates of perceived financial exploitation in older adults: Preliminary findings from the Finance, Cognition, and Health in Elders Study (FINCHES). Aging Ment Health 24:740–746.
1.
Weissberger GH, Mosqueda L, Nguyen AL, Axelrod J, Nguyen CP, Boyle PA, Spreng N, Han SD. 2020. Functional Connectivity Correlates of Perceived Financial Exploitation in Older Adults. Front Aging Neurosci 12:583433.
1.
Viedma-Guiard E, Guidoux C, Amarenco P, Meseguer E. 2020. Aortic Sources of Embolism. Front Neurol 11:606663.
1.
Varela LM, Meseguer E, Lapergue B, Couret D, Amarenco P, Meilhac O. 2020. Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke. J Clin Med 9.
1.
Vallée A, Gabet A, Grave C, Sorbets E, Blacher J, Olié V. 2020. Patterns of hypertension management in France in 2015: The ESTEBAN survey. J Clin Hypertens (Greenwich) 22:663–672.
1.
Vallée A, Blacher J, Cariou A, Sorbets E. 2020. Blended Learning Compared to Traditional Learning in Medical Education: Systematic Review and Meta-Analysis. J Med Internet Res 22:e16504.
1.
Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann FJ, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle JF, Filipiak KJ, van Geuns RJ, Soliman O, Tijssen J, Rademaker-Havinga T, Storey RF, Hamm C, Steg PG, Windecker S, Onuma Y, Valgimigli M, Serruys PW. 2020. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. Eur Heart J Cardiovasc Pharmacother 6:222–230.
1.
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG. 2020. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J 41:4114–4123.
1.
Tran-Dinh A, Levoye A, Couret D, Galle-Treger L, Moreau M, Delbosc S, Hoteit C, Montravers P, Amarenco P, Huby T, Meilhac O. 2020. High-Density Lipoprotein Therapy in Stroke: Evaluation of Endothelial SR-BI-Dependent Neuroprotective Effects. Int J Mol Sci 22.
1.
Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang CC, Kogame N, Spitzer E, Buszman PE, van Geuns RM, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen JGP, Jüni P, Hamm C, Steg PG, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys PW. 2020. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention 15:e1605–e1614.
1.
Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP. 2020. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). Am J Cardiol 125:735–743.
1.
Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Louriero R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Kuck KH, Lauten A, Lurz J, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Khattab AA, Thiele H, Unterhuber M, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, Hahn RT. 2020. Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry. JACC Cardiovasc Interv 13:554–564.
1.
Takahashi K, Wang R, Kawashima H, Tomaniak M, Gao C, Ono M, Hara H, Wykrzykowska JJ, de Winter RJ, Werner N, Teiger E, Almeida M, Barraud P, Lantelme P, Barlis P, Garg S, Hamm C, Steg PG, Onuma Y, Vranckx P, Windecker S, Valgimigli M, Serruys PW. 2020. Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. Int J Cardiol 320:27–34.
1.
Szarek M, Amarenco P, Callahan A, Goldstein LB, Sillesen H, Welch KM. 2020. Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond. J Am Coll Cardiol 76:886–888.
1.
Takahashi K, Kogame N, Tomaniak M, Chichareon P, Chang CC, Modolo R, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Buszman P, Bolognese L, Tumscitz C, Żmudka K, Aminian A, Vrolix M, Petrov I, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Onuma Y, Valgimigli M, Windecker S, Vranckx P, Garg S, Serruys PW. 2020. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clin Res Cardiol 109:918–929.
1.
Takahashi K, Chichareon P, Modolo R, Kogame N, Chang CC, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Stoll HP, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys PW. 2020. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention 16:634–644.
1.
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM. 2020. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol 75:2110–2118.
1.
Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. 2020. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. J Am Coll Cardiol 75:238–240.
1.
Sorrentino S, Sartori S, Baber U, Claessen BE, Giustino G, Chandrasekhar J, Chandiramani R, Cohen DJ, Henry TD, Guedeney P, Ariti C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Urban P, Mehran R. 2020. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv 13:e008226.
1.
Sorbets E, Steg PG. 2020. Direct-acting Anticoagulants in Chronic Coronary Syndromes. Eur Cardiol 15:1–7.
1.
Sorbets E, Cinaud A. 2020. Why Improve Our Knowledge and Clinical Practice in the Management of Patients With Coronary Vasospasm? JACC Cardiovasc Interv 13:1877–1879.
1.
Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, Ford I, Greenlaw N, Kalra PR, Parma Z, Shalnova S, Tardif JC, Tendera M, Zamorano JL, Vidal-Petiot E, Steg PG. 2020. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J 41:347–356.
1.
Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, Bourrier A, Le Gall G, Lalande V, De Rougemont A, Kirchgesner J, Daguenel A, Cachanado M, Rousseau A, Drouet É, Rosenzwajg M, Hagege H, Dray X, Klatzman D, Marteau P, Beaugerie L, Simon T. 2020. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study. Microbiome 8:12.
1.
Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque JN, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet JP, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G. 2020. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet 396:1737–1744.
1.
Silvain J, Cayla G, Beygui F, Range G, Lattuca B, Collet JP, Dillinger JG, Boueri Z, Brunel P, Pouillot C, Boccara F, Christiaens L, Labeque JN, Lhermusier T, Georges JL, Bellemain-Appaix A, Le Breton H, Hauguel-Moreau M, Saint-Etienne C, Caussin C, Jourda F, Motovska Z, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Vicaut E, Montalescot G. 2020. Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. Am Heart J 225:27–37.
1.
Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Bossard M, Bangalore S, Schwalm JD, Velianou JL, Valettas N, Sibbald M, Rodés-Cabau J, Ducas J, Cohen EA, Bagai A, Rinfret S, Newby DE, Feldman L, Laster SB, Lang IM, Mills JD, Cairns JA, Mehta SR. 2020. Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. J Am Coll Cardiol 76:1277–1286.
1.
Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL. 2020. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 141:1608–1617.
1.
Puymirat E, Simon T, de Bruyne B, Montalescot G, Steg G, Cayla G, Durand-Zaleski I, Blanchard D, Danchin N, Chatellier G. 2020. Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial. Am Heart J 222:1–7.
1.
Potier L, Roussel R, Zeller M, Schiele F, Puymirat E, Simon T, Danchin N. 2020. Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program. Diabetes Care 43:e43–e44.
1.
Popovic B, Sorbets E, Abtan J, Cohen M, Pollack Jr CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG. 2020. Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Eur Heart J Acute Cardiovasc Care 2048872619896205.
1.
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D, Yasuda S, Hedman K, Rennie KL, Sundell KA. 2020. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clin Cardiol 43:24–32.
1.
Philippon AL, Dumont M, Jimenez S, Salhi S, Cachanado M, Durand-Zaleski I, Simon T, Freund Y. 2020. MOdified DIagnostic strateGy to safely ruLe-out pulmonary embolism In the emergency depArtment: study protocol for the Non-Inferiority MODIGLIANI cluster cross-over randomized trial. Trials 21:458.
1.
Pico F, Lapergue B, Ferrigno M, Rosso C, Meseguer E, Chadenat ML, Bourdain F, Obadia M, Hirel C, Duong DL, Deltour S, Aegerter P, Labreuche J, Cattenoy A, Smadja D, Hosseini H, Guillon B, Wolff V, Samson Y, Cordonnier C, Amarenco P. 2020. Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke: The RESCUE BRAIN Randomized Clinical Trial. JAMA Neurol 77:725–734.
1.
Pico F, Lapergue B, Amarenco P. 2020. Remote Ischemic Perconditioning for the Treatment of Acute Ischemic Stroke-Reply. JAMA Neurol 77:1452.
1.
Ozen G, Benyahia C, Mani S, Boukais K, Silverstein AM, Bayles R, Nelsen AC, Castier Y, Danel C, Mal H, Clapp LH, Longrois D, Norel X. 2020. Bronchodilation induced by PGE(2) is impaired in Group III pulmonary hypertension. Br J Pharmacol 177:161–174.
1.
Ozen G, Benyahia C, Amgoud Y, Patel J, Abdelazeem H, Bouhadoun A, Yung S, Li F, Mahieddine Y, Silverstein AM, Castier Y, Cazes A, Longrois D, Clapp LH, Norel X. 2020. Interaction between PGI(2) and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients. Prostaglandins Other Lipid Mediat 146:106388.
1.
Ozen G, Amgoud Y, Abdelazeem H, Mani S, Benyahia C, Bouhadoun A, Tran-Dinh A, Castier Y, Guyard A, Longrois D, Silverstein AM, Norel X. 2020. Downregulation of PGI(2) pathway in Pulmonary Hypertension Group-III patients. Prostaglandins Leukot Essent Fatty Acids 160:102158.
1.
Ozen G, Aljesri K, Celik Z, Turkyılmaz G, Turkyılmaz S, Teskin O, Norel X, Topal G. 2020. Mechanism of thromboxane receptor-induced vasoconstriction in human saphenous vein. Prostaglandins Other Lipid Mediat 151:106476.
1.
Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, Modolo R, Hara H, Gao C, Wang R, Walsh S, Suryapranata H, da Silva PC, Cotton J, Koning R, Akin I, Rensing B, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Windecker S, Storey RF, Onuma Y, Vranckx P, Serruys PW. 2020. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clin Res Cardiol 109:1125–1139.
1.
Ong E, Meseguer E, Guidoux C, Lavallée PC, Hobeanu C, Charles H, Labreuche J, Cabrejo L, Martin-Bechet A, Rigual R, Nighoghossian N, Amarenco P. 2020. Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. Stroke 51:2355–2363.
1.
Norel X, Sugimoto Y, Ozen G, Abdelazeem H, Amgoud Y, Bouhadoun A, Bassiouni W, Goepp M, Mani S, Manikpurage HD, Senbel A, Longrois D, Heinemann A, Yao C, Clapp LH. 2020. International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E(2) Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions. Pharmacol Rev 72:910–968.
1.
Nicolau JC, Brieger D, Owen R, Furtado RHM, Goodman SG, Cohen MG, Simon T, Westermann D, Granger CB, Grieve R, Yasuda S, Chen J, Hedman K, Mellström C, Brandrup-Wognsen G, Pocock SJ. 2020. Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. Clin Cardiol 43:1352–1361.
1.
Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM. 2019. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clin Chem 65:781–790.
1.
Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW. 2019. The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clin Cardiol 42:797–805.
1.
Yeh RW, Kereiakes DJ, Secemsky EA, Steg PG, Mauri L. 2019. The DAPT Score in Sweden: Successful Validation, Flawed Interpretation. J Am Coll Cardiol 73:113–114.
1.
Wang Y, Johnston SC, Bath PM, Grotta JC, Pan Y, Amarenco P, Wang Y, Simon T, Kim JS, Jeng JS, Liu L, Lin Y, Wong KSL, Wang D, Li H. 2019. Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. Bmj 364:l895.
1.
Vogel B, Chandrasekhar J, Baber U, Mastoris I, Sartori S, Aquino M, Krucoff MW, Moliterno DJ, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini AS, Farhan S, Sorrentino S, Faggioni M, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen DJ, Stuckey T, Ariti C, Dangas GD, Pocock S, Mehran R. 2019. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost 119:1704–1711.
1.
Vidal-Petiot E, Greenlaw N, Kalra PR, Garcia-Moll X, Tardif JC, Ford I, Zamorano J, Ferrari R, Tendera M, Fox KM, Steg PG, On Behalf Of The Clarify I. 2019. Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. J Clin Med 9.
1.
Uchiyama S, Hoshino T, Sissani L, Linsay MT, Kamiyama K, Nakase T, Kitagawa K, Minematsu K, Todo K, Okada Y, Nakagawara J, Nagata K, Yamagami H, Yamaguchi T, Amarenco P. 2019. Japanese Versus Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke: Subanalysis of TIA registry.org. J Stroke Cerebrovasc Dis 28:2232–2241.
1.
Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF, Dangas GD, Bhatt DL, Angiolillo DJ, Hamm C, Valgimigli M, Windecker S, Steg PG, Vranckx P, Serruys PW. 2019. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. JAMA Cardiol 4:1092–1101.
1.
Thomas MR, James SK, Becker RC, Himmelmann A, Katus HA, Cannon CP, Steg PG, Siegbahn A, Lakic T, Storey RF, Wallentin L. 2019. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. Eur Heart J Acute Cardiovasc Care 2048872619878075.
1.
Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP. 2019. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. JACC Cardiovasc Interv 12:2331–2341.
1.
Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferrières J, Schiele F, Simon T, Danchin N, Puymirat E. 2019. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. Eur J Prev Cardiol 26:411–419.
1.
Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntané-Carol G, Nazif T, Nickening G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, Maisano F. 2019. Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. J Am Coll Cardiol 74:2998–3008.
1.
Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, Denti P, Deuschl F, Englmeier A, Fam N, Frerker C, Hausleiter J, Himbert D, Ho EC, Juliard JM, Kaple R, Kreidel F, Kuck KH, Ancona M, Lauten A, Lurz P, Mehr M, Nazif T, Nickening G, Pedrazzini G, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Sievert K, Tang GHL, Tanner FC, Vahanian A, Webb JG, Windecker S, Yzeiray E, Zuber M, Maisano F, Leon MB, Hahn RT. 2019. Outcomes After Current Transcatheter Tricuspid Valve Intervention: Mid-Term Results From the International TriValve Registry. JACC Cardiovasc Interv 12:155–165.
1.
Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R, Kogame N, Magro M, Chowdhary S, Eitel I, Zweiker R, Ong P, Ottesen MM, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Garg S, Stoll HP, Hamm C, Steg PG, Onuma Y, Valgimigli M, Vranckx P, Carrie D, Windecker S. 2019. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. J Am Coll Cardiol 74:2015–2027.
1.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA. 2019. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med 381:1309–1320.
1.
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. 2019. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation 140:103–112.
1.
Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE. 2019. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol 124:1813–1820.
1.
Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, Tendera M, Ferrari R, Merkely B, Parkhomenko A, Reid C, Tardif JC, Fox KM. 2019. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J 40:1399–1407.
1.
Shen L, Patel JA, Norel X, Moledina S, Whittle BJ, von Kessler K, Sista P, Clapp LH. 2019. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension. Biochem Pharmacol 166:242–252.
1.
Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M. 2019. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J 40:2595–2604.
1.
Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Spitzer E, Walsh SJ, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen JGP, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt FWA. 2019. Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention 15:e1090–e1098.
1.
Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antoniucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, Moliterno D, Colombo A, Pocock S, Dangas G, Mehran R. 2019. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol 123:709–716.
1.
Schiele F, Puymirat E, Ferrières J, Simon T, Fox KAA, Eikelboom J, Danchin N. 2019. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. Int J Cardiol 278:7–13.
1.
Raynal PA, Cachanado M, Truchot J, Damas-Perrichet C, Feral-Pierssens AL, Goulet H, Deltour S, Boussouar S, Donciu V, Simon T, Freund Y, Philippon AL. 2019. Prevalence of pulmonary embolism in emergency department patients with isolated syncope: a prospective cohort study. Eur J Emerg Med 26:458–461.
1.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG. 2019. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 7:618–628.
1.
Puymirat E, Bonaca M, Iliou MC, Tea V, Ducrocq G, Douard H, Labrunee M, Plastaras P, Chevallereau P, Taldir G, Bataille V, Ferrières J, Schiele F, Simon T, Danchin N. 2019. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. Arch Cardiovasc Dis 112:459–468.
1.
Puymirat E, Cayla G, Cottin Y, Elbaz M, Henry P, Gerbaud E, Lemesle G, Popovic B, Labèque JN, Roubille F, Andrieu S, Farah B, Schiele F, Ferrières J, Simon T, Danchin N. 2019. Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015. Am Heart J 214:97–106.
1.
Puymirat E, Bonaca M, Fumery M, Tea V, Aissaoui N, Lemesles G, Bonello L, Ducrocq G, Cayla G, Ferrières J, Schiele F, Simon T, Danchin N. 2019. Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clin Cardiol 42:227–234.
1.
Picard F, Van Ganse E, Ducrocq G, Danchin N, Falissard B, Hanon O, Belhassen M, Ginoux M, Lefevre C, Cotte FE, Mahé I, Steg PG. 2019. EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study. Clin Cardiol 42:851–859.
1.
Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. 2019. Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. J Am Coll Cardiol 73:1362–1364.
1.
Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, others. 2019. Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circ Genom Precis Med 12:e002470.
1.
Parma Z, Young R, Roleder T, Marona M, Ford I, Tendera M, Steg PG, Stępińska J. 2019. Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease versus other European countries: data from the CLARIFY registry. Pol Arch Intern Med 129:327–334.
1.
Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, Zhao X, Liu L, Wang D, Meng X, Wang Y. 2019. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol 76:552–560.
1.
Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW. 2019. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. Circ Cardiovasc Interv 12:e007541.
1.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. 2019. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J 40:1553–1562.
1.
Ntaios G, Pearce LA, Meseguer E, Endres M, Amarenco P, Ozturk S, Lang W, Bornstein NM, Molina CA, Pagola J, Mundl H, Berkowitz SD, Liu YY, Sen S, Connolly SJ, Hart RG. 2019. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke 50:3184–3190.
1.
Nickenig G, Weber M, Schueler R, Hausleiter J, Näbauer M, von Bardeleben RS, Sotiriou E, Schäfer U, Deuschl F, Kuck KH, Kreidel F, Juliard JM, Brochet E, Latib A, Agricola E, Baldus S, Friedrichs K, Vandrangi P, Verta P, Hahn RT, Maisano F. 2019. 6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. J Am Coll Cardiol 73:1905–1915.
1.
Nguyen CT, Mestman JH. 2019. Postpartum Thyroiditis. Clin Obstet Gynecol 62:359–364.
1.
Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG. 2019. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke 50:2477–2485.
1.
Nguyen CT, Mestman JH. 2019. Graves’ hyperthyroidism in pregnancy. Curr Opin Endocrinol Diabetes Obes 26:232–240.
1.
Molina CA, Johnston SC, Ladenvall P, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Knutsson M, Minematsu K, Röther J, Wang Y, Wong KSL. 2019. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. Stroke 50:675–682.
1.
Naccache JM, Montil M, Cadranel J, Cachanado M, Cottin V, Crestani B, Valeyre D, Wallaert B, Simon T, Nunes H. 2019. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulm Med 19:75.
1.
Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-Sendón J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg PG, Avezum Á, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley B, Kedev S, Sutton A, Oliver R, Rodés-Cabau J, Stanković G, Welsh R, Lavi S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA. 2019. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med 381:1411–1421.
1.
Mas JL, Derex L, Guérin P, Guillon B, Habib G, Juliard JM, Marijon E, Massardier E, Meneveau N, Vuillier F. 2019. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology. Arch Cardiovasc Dis 112:532–542.
1.
Martin M, Bérard L, Simon T, Leblanc J. 2019. [Nurses’ participation in clinical research projects: a cross-sectional study in five hospitals]. Soins 64:13–19.
1.
Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. 2019. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC Cardiovasc Interv 12:2346–2355.
1.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. 2019. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. Am Heart J 212:13–22.
1.
Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CP. 2019. Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. J Am Coll Cardiol 74:2431–2433.
1.
Lefèvre JH, Mineur L, Cachanado M, Denost Q, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasguen N, Creavin B, Simon T, Parc Y. 2019. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years’ Follow-up Results of the Greccar-6 Randomized Multicenter Trial. Ann Surg 270:747–754.
1.
Zeng X, Lincoff AM, Schulz-Schüpke S, Steg PG, Elbez Y, Mehran R, Stone GW, McAndrew T, Lin J, Zhang X, Shi W, Lei H, Jing Z, Huang W. 2018. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. J Cardiol 71:494–504.
1.
Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Himmelmann A, Kasner SE, Knutsson M, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC. 2018. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke 49:1678–1685.
1.
Weissberger GH, Nation DA, Nguyen CP, Bondi MW, Han SD. 2018. Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans. Neurosci Biobehav Rev 94:49–58.
1.
Vogin G, Merlin JL, Rousseau A, Peiffert D, Harlé A, Husson M, Hajj LE, Levitchi M, Simon T, Simon JM. 2018. Absence of correlation between radiation-induced CD8 T-lymphocyte apoptosis and sequelae in patients with prostate cancer accidentally overexposed to radiation. Oncotarget 9:32680–32689.
1.
Vidal-Petiot E, Sorbets E, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. 2018. Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. Eur Heart J 39:3855–3863.
1.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S. 2018. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392:940–949.
1.
Villeret B, Dieu A, Straube M, Solhonne B, Miklavc P, Hamadi S, Le Borgne R, Mailleux A, Norel X, Aerts J, Diallo D, Rouzet F, Dietl P, Sallenave JM, Garcia-Verdugo I. 2018. Silver Nanoparticles Impair Retinoic Acid-Inducible Gene I-Mediated Mitochondrial Antiviral Immunity by Blocking the Autophagic Flux in Lung Epithelial Cells. ACS Nano 12:1188–1202.
1.
Vidal-Petiot E, Elbez Y, Lüscher TF, Fox KM, Steg PG. 2018. The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients. Eur Heart J 39:4040–4041.
1.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2018. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–260.
1.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2018. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed) 71:42.
1.
Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2018. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 53:34–78.
1.
Vahanian A, Brochet E, Juliard JM. 2018. Guidelines Recommendations on the Treatment of Tricuspid Regurgitation. Where Are We and Where Do We Go With Transcatheter Valve Intervention. Front Cardiovasc Med 5:37.
1.
Touboul PJ, Labreuche J, Bruckert E, Schargrodsky H, Prati P, Tosetto A, Hernandez-Hernandez R, Woo KS, Silva H, Vicaut E, Amarenco P. 2018. Corrigendum to “HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement” [Atherosclerosis 232 (2014) 65-71]. Atherosclerosis 273:158.
1.
Teiger E, Thambo JB, Defaye P, Hermida JS, Abbey S, Klug D, Juliard JM, Pasquie JL, Rioufol G, Lepillier A, Elbaz M, Horvilleur J, Brenot P, Pierre B, Le Corvoisier P. 2018. Percutaneous Left Atrial Appendage Closure Is a Reasonable Option for Patients With Atrial Fibrillation at High Risk for Cerebrovascular Events. Circ Cardiovasc Interv 11:e005841.
1.
Steg PG, Wijns W. 2018. Towards Drugs and Devices Synergy. A new session track at EuroPCR: PCR clinical algorithms. EuroIntervention 13:1991–1992.
1.
Steg PG, Popovic B. 2018. Emergency Coronary Angiography After Out-of-Hospital Cardiac Arrest: Is It Essential or Futile? Circ Cardiovasc Interv 11:e006804.
1.
Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2018. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol 122:1638–1646.
1.
Steg PG, Bhatt DL. 2018. Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics? Circulation 137:1429–1431.
1.
Simon JM, Thomas F, Czernichow S, Hanon O, Lemogne C, Simon T, Pannier B, Danchin N. 2018. Hyperglycaemia is associated with cancer-related but not non-cancer-related deaths: evidence from the IPC cohort. Diabetologia 61:1089–1097.
1.
Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ, Pieper KS, Becker RC, James SK, Storey RF, Steg PG, Held C, Himmelmann A, Mahaffey KW, Wallentin L, Cannon CP. 2018. Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. Am Heart J 202:54–60.
1.
Roussel R, Steg PG, Mohammedi K, Marre M, Potier L. 2018. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions. Diabetes Obes Metab 20:238–244.
1.
Rakowski T, Dudek D, van ’t Hof A, Ten Berg J, Soulat L, Zeymer U, Lapostolle F, Anthopoulos P, Bernstein D, Deliargyris EN, Steg PG. 2018. Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. Eur Heart J Acute Cardiovasc Care 7:514–521.
1.
Puymirat E, Simon T, Danchin N. 2018. Response by Puymirat et al to Letter Regarding Article, “Acute Myocardial Infarction Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.” Circulation 137:2307–2308.
1.
Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. 2018. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 206:80–93.
1.
Picard F, Ducrocq G, Danchin N, Falissard B, Hanon O, Mahe I, Touzé E, Steg PG. 2018. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study. Arch Cardiovasc Dis 111:349–356.
1.
Patel JA, Shen L, Hall SM, Benyahia C, Norel X, McAnulty RJ, Moledina S, Silverstein AM, Whittle BJ, Clapp LH. 2018. Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells. Int J Mol Sci 19.
1.
Pevnick JM, Nguyen C, Jackevicius CA, Palmer KA, Shane R, Cook-Wiens G, Rogatko A, Bear M, Rosen O, Seki D, Doyle B, Desai A, Bell DS. 2018. Improving admission medication reconciliation with pharmacists or pharmacy technicians in the emergency department: a randomised controlled trial. BMJ Qual Saf 27:512–520.
1.
Nguyen CT, Sasso EB, Barton L, Mestman JH. 2018. Graves’ hyperthyroidism in pregnancy: a clinical review. Clin Diabetes Endocrinol 4:4.
1.
Nguyen CT, Lin S, Clark H, Hovan A, Wu J. 2018. Salivary flow rate after conventional and intensity-modulated radiation therapy. J Am Dent Assoc 149:432–441.
1.
Nguyen CT, Lee VS, Wu J. 2018. An Acrylic Immobilization Bite Block for Use During Radiation Therapy: Description of a New Technique. Int J Prosthodont 31:338–341.
1.
Mawhin MA, Tilly P, Zirka G, Charles AL, Slimani F, Vonesch JL, Michel JB, Bäck M, Norel X, Fabre JE. 2018. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia. Cardiovasc Res 114:1656–1666.
1.
Magnuson EA, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Braunwald E, Sabatine MS, Cohen DJ. 2018. Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. J Am Coll Cardiol 71:108.
1.
Manzo-Silberman S, Couturaud F, Charpentier S, Auffret V, El Khoury C, Le Breton H, Belle L, Marlière S, Zeller M, Cottin Y, Danchin N, Simon T, Schiele F, Gilard M. 2018. Influence of gender on delays and early mortality in ST-segment elevation myocardial infarction: Insight from the first French Metaregistry, 2005-2012 patient-level pooled analysis. Int J Cardiol 262:1–8.
1.
Loyeau A, Benamer H, Bataille S, Tepper S, Boche T, Lamhaut L, Pirès V, Simon B, Dupas F, Weisslinger L, Le Bail G, Allonneau A, Juliard JM, Lambert Y, Lapostolle F. 2018. Evolution of ST-Elevation Acute Myocardial Infarction Prevalence by Gender Assessed Age Pyramid Analysis-The Piramyd Study. J Clin Med 7.
1.
Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L. 2018. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol 3:1160–1166.
1.
Leblanc J, Hejblum G, Costagliola D, Durand-Zaleski I, Lert F, de Truchis P, Verbeke G, Rousseau A, Piquet H, Simon F, Pateron D, Simon T, Crémieux AC. 2018. Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial. Ann Emerg Med 72:41-53.e9.
1.
Le Bouc R, Clarençon F, Meseguer E, Lapergue B, Consoli A, Turc G, Naggara O, Duong DL, Servan J, Reiner P, Labeyrie MA, Fisselier M, Blanc R, Farhat W, Pires C, Zuber M, Obadia M, Mazighi M, Pico F, Mas JL, Amarenco P, Samson Y. 2018. Efficacy of Endovascular Therapy in Acute Ischemic Stroke Depends on Age and Clinical Severity. Stroke 49:1686–1694.
1.
Kratz RJ, Nguyen CT, Walton JN, MacDonald D. 2018. Dental Students’ Interpretations of Digital Panoramic Radiographs on Completely Edentate Patients. J Dent Educ 82:313–321.
1.
Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL. 2018. New prospects for PCSK9 inhibition? Eur Heart J 39:2600–2601.
1.
Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL. 2018. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J 39:1131–1143.
1.
Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, Valgimigli M, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP. 2018. The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. Eur J Prev Cardiol 25:377–387.
1.
Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ. 2018. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol 72:141–153.
1.
Kasner SE, Lavados P, Sharma M, Wang Y, Wang Y, Dávalos A, Shamalov N, Cunha L, Lindgren A, Mikulik R, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi R, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni DS, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, DeVries Basson MM, Endres M, Muir K, Bornstein N, Ozturk S, O’Donnell M, Mundl H, Pater C, Weitz J, Peacock WF, Swaminathan B, Kirsch B, Berkowitz SD, Peters G, Pare G, Themeles E, Shoamanesh A, Connolly SJ, Hart RG. 2018. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. J Stroke Cerebrovasc Dis 27:1673–1682.
1.
Joner M, Koppara T, Byrne RA, Castellanos MI, Lewerich J, Novotny J, Guagliumi G, Xhepa E, Adriaenssens T, Godschalk TC, Malik N, Alfonso F, Tada T, Neumann FJ, Desmet W, Ten Berg JM, Gershlick AH, Feldman LJ, Massberg S, Kastrati A. 2018. Neoatherosclerosis in Patients With Coronary Stent Thrombosis: Findings From Optical Coherence Tomography Imaging (A Report of the PRESTIGE Consortium). JACC Cardiovasc Interv 11:1340–1350.
1.
Isorni MA, Aissaoui N, Angoulvant D, Bonello L, Lemesle G, Delmas C, Henry P, Schiele F, Ferrières J, Simon T, Danchin N, Puymirat É. 2018. Temporal trends in clinical characteristics and management according to sex in patients with cardiogenic shock after acute myocardial infarction: The FAST-MI programme. Arch Cardiovasc Dis 111:555–563.
1.
Hoshino T, Sissani L, Labreuche J, Ducrocq G, Lavallée PC, Meseguer E, Guidoux C, Cabrejo L, Hobeanu C, Gongora-Rivera F, Touboul PJ, Steg PG, Amarenco P. 2018. Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease. JAMA Neurol 75:203–211.
1.
Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L. 2018. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol 72:721–733.
1.
Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O’Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ. 2018. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med 378:2191–2201.
1.
Hardley MT, Chon AH, Mestman J, Nguyen CT, Geffner ME, Chmait RH. 2018. Iodine-Induced Fetal Hypothyroidism: Diagnosis and Treatment with Intra-Amniotic Levothyroxine. Horm Res Paediatr 90:419–423.
1.
Haddad B, Lefèvre G, Rousseau A, Robert T, Saheb S, Rafat C, Bornes M, Petit-Hoang C, Richard F, Lecarpentier E, Tsatsaris V, Guibourdenche J, Corchia A, Rondeau E, Simon T, Hertig A. 2018. LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: Report of two cases from a discontinued phase II trial. Eur J Obstet Gynecol Reprod Biol 231:70–74.
1.
Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP, Meyers CM, Rosenberg Y, Simon T, Stough WG, Zalewski A, Zariffa N, Temple R. 2017. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart 103:1156–1162.
1.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. 2017. Corrigendum to “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease” [Am Heart J 181 (2016) 92-100]. Am Heart J 184:156.
1.
Westermann D, Goodman SG, Nicolau JC, Requena G, Maguire A, Chen JY, Granger CB, Grieve R, Pocock SJ, Blankenberg S, Vega AM, Yasuda S, Simon T, Brieger D. 2017. Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. Clin Cardiol 40:1197–1204.
1.
Wang Y, Minematsu K, Wong KS, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Molina CA, Johnston SC. 2017. Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Stroke 48:167–173.
1.
Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PG. 2017. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. Eur Heart J 38:2813–2822.
1.
Vidal-Petiot E, Bhatt DL, Fox KM, Steg PG. 2017. Blood pressure and cardiovascular outcomes: a closer look - Authors’ reply. Lancet 389:1296–1297.
1.
Varshney A, Steg PG, Elbez Y, Sorbets E, Eagle KA, Bhatt DL. 2017. Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis. Int J Cardiol 243:95–97.
1.
Vedin O, Hagström E, Östlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C. 2017. Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. Int J Cardiol 245:271–276.
1.
Van’t Hof A, Giannini F, Ten Berg J, Tolsma R, Clemmensen P, Bernstein D, Coste P, Goldstein P, Zeymer U, Hamm C, Deliargyris E, Steg PG. 2017. ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy. Eur Heart J Acute Cardiovasc Care 6:404–411.
1.
Vacchina V, Séby F, Chekri R, Verdeil J, Dumont J, Hulin M, Sirot V, Volatier JL, Serreau R, Rousseau A, Simon T, Guérin T. 2017. Optimization and validation of the methods for the total mercury and methylmercury determination in breast milk. Talanta 167:404–410.
1.
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. 2017. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost 117:940–947.
1.
Terzian Z, Gasser TC, Blackwell F, Hyafil F, Louedec L, Deschildre C, Ghodbane W, Dorent R, Nicoletti A, Morvan M, Nejjari M, Feldman L, Pavon-Djavid G, Michel JB. 2017. Peristrut microhemorrhages: a possible cause of in-stent neoatherosclerosis? Cardiovasc Pathol 26:30–38.
1.
Taramasso M, Hahn RT, Alessandrini H, Latib A, Attinger-Toller A, Braun D, Brochet E, Connelly KA, Denti P, Deuschl F, Englmaier A, Fam N, Frerker C, Hausleiter J, Juliard JM, Kaple R, Kreidel F, Kuck KH, Kuwata S, Ancona M, Malasa M, Nazif T, Nickenig G, Nietlispach F, Pozzoli A, Schäfer U, Schofer J, Schueler R, Tang G, Vahanian A, Webb JG, Yzeiraj E, Maisano F, Leon MB. 2017. The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair? JACC Cardiovasc Interv 10:1982–1990.
1.
Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. 2017. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol 70:1689–1700.
1.
Steg PG, Harrington RA, Himmelmann A, James SK, Pieper KS, Wallentin L. 2017. Unreliable Observations from a Confounded Analysis of a Skewed Database. Am J Med 130:e355–e356.
1.
Stewart RAH, Hagström E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, López-Sendón JL, Mohler 3rd ER, Hadziosmanovic N, Krug-Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin L. 2017. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. J Am Heart Assoc 6.
1.
Steinhilber D, Uydeş-Doğan BS, Topal G, Clària J, Norel X, Schebb NH, Bannenberg G. 2017. Editorial-Special issue of the 6th European Workshop on Lipid Mediators. Prostaglandins Other Lipid Mediat 133:1–3.
1.
Steg PG, Simon T. 2017. Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials? Eur Heart J 38:1044–1047.
1.
Sorbets E, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG. 2017. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol 40:797–806.
1.
Simon T, Danchin N. 2017. Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke. Circulation 135:34–37.
1.
Sochala M, Wahbi K, Sorbets E, Lazarus A, Bécane HM, Stojkovic T, Fayssoil A, Laforêt P, Béhin A, Sroussi M, Eymard B, Duboc D, Meune C. 2017. Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1. J Neuromuscul Dis 4:175–181.
1.
Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R. 2017. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv 10.
1.
Schiele F, Gale CP, Simon T, Fox KAA, Bueno H, Lettino M, Tubaro M, Puymirat E, Ferrières J, Meneveau N, Danchin N. 2017. Assessment of Quality Indicators for Acute Myocardial Infarction in the FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) Registries. Circ Cardiovasc Qual Outcomes 10.
1.
Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre PF, Kere D, Doridot V, D’Halluin G, Fritel X, Pouget N, Jankowski C, Mazouni C, Simon T, Coutant C. 2017. Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study. Br J Cancer 116:1135–1140.
1.
Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P. 2017. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int 92:227–237.
1.
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. 2017. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med 376:1517–1526.
1.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. 2017. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med 376:1527–1539.
1.
Qaderdan K, Vos GA, McAndrew T, Steg PG, Hamm CW, Van’t Hof A, Mehran R, Deliargyris EN, Bernstein D, Stone GW, Ten Berg JM. 2017. Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. Am Heart J 194:73–82.
1.
Puymirat E, Caudron J, Steg PG, Lemesle G, Cottin Y, Coste P, Schiele F, de Labriolle A, Bataille V, Ferrières J, Simon T, Danchin N. 2017. Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. Eur Heart J Acute Cardiovasc Care 6:26–33.
1.
Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, Lemesle G, Motreff P, Popovic B, Khalife K, Labèque JN, Perret T, Le Ray C, Orion L, Jouve B, Blanchard D, Peycher P, Silvain J, Steg PG, Goldstein P, Guéret P, Belle L, Aissaoui N, Ferrières J, Schiele F, Danchin N. 2017. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation 136:1908–1919.
1.
Puymirat E, Aissaoui N, Lemesle G, Cottin Y, Coste P, Schiele F, Ferrières J, Simon T, Danchin N. 2017. Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry). Am J Cardiol 119:692–697.
1.
Puymirat E, Aissaoui N, Cayla G, Lafont A, Riant E, Mennuni M, Saint-Jean O, Blanchard D, Jourdain P, Elbaz M, Henry P, Bataille V, Drouet E, Mulak G, Schiele F, Ferrières J, Simon T, Danchin N. 2017. Changes in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early Management. Am J Med 130:555–563.
1.
Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG. 2017. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103:1339–1346.
1.
Puymirat E, Aissaoui N, Bonello L, Cayla G, Labèque JN, Nallet O, Motreff P, Varenne O, Schiele F, Ferrières J, Simon T, Danchin N. 2017. Clinical outcomes according to symptom presentation in patients with acute myocardial infarction: Results from the FAST-MI 2010 registry. Clin Cardiol 40:1256–1263.
1.
Pollack Jr CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP. 2017. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol 40:390–398.
1.
Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Gibson CM, White HD, Storey RF. 2017. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost 117:1093–1100.
1.
Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif JC, Morais J, Gamba MA, Kääb S, Tendera For The Clarify Investigators M. 2017. Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry. Pol Arch Intern Med 127:107–114.
1.
Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Ahn JM, Park SJ, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. 2017. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol 69:2011–2022.
1.
Ozen G, Gomez I, Daci A, Deschildre C, Boubaya L, Teskin O, Uydeş-Doğan BS, Jakobsson PJ, Longrois D, Topal G, Norel X. 2017. Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI(2) : a safer alternative to COX-2 inhibition. Br J Pharmacol 174:4087–4098.
1.
Ollivier V, Roques C, Receveur N, Gratz M, Feldman L, Letourneur D, Gachet C, Mangin PH, Jandrot-Perrus M. 2017. Bioreactivity of stent material: Activation of platelets, coagulation, leukocytes and endothelial cell dysfunction in vitro. Platelets 28:529–539.
1.
Nguyen CB, Shane R, Bell DS, Cook-Wiens G, Pevnick JM. 2017. A Time and Motion Study of Pharmacists and Pharmacy Technicians Obtaining Admission Medication Histories. J Hosp Med 12:180–183.
1.
Mazighi M, Meseguer E, Labreuche J, Miroux P, Le Gall C, Roy P, Tubach F, Amarenco P. 2017. TRUST-tPA trial: Telemedicine for remote collaboration with urgentists for stroke-tPA treatment. J Telemed Telecare 23:174–180.
1.
Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G. 2017. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med 377:1011–1021.
1.
Manzo-Silberman S, Nicaise-Roland P, Neukirch C, Tubach F, Huisse MG, Chollet-Martin S, Abergel H, Driss F, Alfaiate T, Ajzenberg N, Steg PG. 2017. Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. Eur Heart J Cardiovasc Pharmacother 3:77–81.
1.
Magnuson EA, Li H, Wang K, Vilain K, Shafiq A, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Braunwald E, Sabatine MS, Cohen DJ. 2017. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol 70:527–538.
1.
Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagström E, Held C, Koenig W, Östlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, März W, Wallentin L. 2017. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol 70:813–826.